PMID- 38360296
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Linking)
VI  - 223
DP  - 2024 Mar
TI  - Porcine interferon-alpha linked to the porcine IgG-Fc induces prolonged and 
      broad-spectrum antiviral effects against foot-and-mouth disease virus.
PG  - 105836
LID - S0166-3542(24)00044-5 [pii]
LID - 10.1016/j.antiviral.2024.105836 [doi]
AB  - Foot-and-mouth disease (FMD) is an economically important disease, and the FMD 
      virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled 
      through vaccination. However, commercial FMD vaccines are only effective 4-7 days 
      after vaccination. Furthermore, FMDV comprises seven serotypes and various 
      topotypes, and these aspects should be considered when selecting a vaccine. 
      Antiviral agents could provide rapid and broad protection against FMDV. 
      Therefore, this study aimed to develop a fusion protein of consensus porcine 
      interferon-alpha and Fc portion of porcine antibody IgG (poIFN-alpha-Fc) using a 
      baculovirus expression system to develop a novel antiviral agent against FMDV. We 
      measured the antiviral effects of the poIFN-alpha-Fc protein against FMDV and the 
      enhanced duration in vitro and in vivo. The broad-spectrum antiviral effects were 
      tested against seven FMDV serotypes, porcine reproductive and respiratory 
      syndrome virus (PRRSV), and bovine enterovirus (BEV). Furthermore, the early 
      protective effects and neutralizing antibody levels were tested by co-injecting 
      poIFN-alpha-Fc and an FMD-inactivated vaccine into mice or pigs. Sustained antiviral 
      effects in pig sera and mice were observed, and pigs injected with a combination 
      of the poIFN-alpha-Fc and an inactivated FMD vaccine were protected against FMDV in a 
      dose-dependent manner at 2- and 4-days post-vaccination. In addition, combined 
      with the inactivated FMD vaccine, poIFN-alpha-Fc increased the neutralizing antibody 
      levels in mice. Therefore, poIFN-alpha-Fc is a potential broad-spectrum antiviral and 
      adjuvant candidate that can be used with inactivated FMD vaccines to protect pigs 
      against FMDV.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Lee, Gyeongmin
AU  - Lee G
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Kim, Aro
AU  - Kim A
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Kang, Hyo Rin
AU  - Kang HR
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Hwang, Ji-Hyeon
AU  - Hwang JH
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Park, Jong-Hyeon
AU  - Park JH
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Lee, Min Ja
AU  - Lee MJ
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Kim, Byounghan
AU  - Kim B
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea.
FAU - Kim, Su-Mi
AU  - Kim SM
AD  - Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine 
      Agency, 177 Hyeoksin 8-ro, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea. 
      Electronic address: beliefsk@korea.kr.
LA  - eng
PT  - Journal Article
DEP - 20240214
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Interferon-alpha)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines)
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Cattle
MH  - Swine
MH  - Animals
MH  - Mice
MH  - *Foot-and-Mouth Disease Virus
MH  - Interferon-alpha/pharmacology
MH  - Antibodies, Neutralizing
MH  - Immunoglobulin G
MH  - *Vaccines
MH  - Antiviral Agents/pharmacology
OTO - NOTNLM
OT  - Antiviral effect
OT  - Fc portion
OT  - Foot-and-mouth disease virus
OT  - Interferon-alpha
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/16 00:42
MHDA- 2024/03/04 06:45
CRDT- 2024/02/15 21:45
PHST- 2023/08/25 00:00 [received]
PHST- 2024/01/22 00:00 [revised]
PHST- 2024/02/13 00:00 [accepted]
PHST- 2024/03/04 06:45 [medline]
PHST- 2024/02/16 00:42 [pubmed]
PHST- 2024/02/15 21:45 [entrez]
AID - S0166-3542(24)00044-5 [pii]
AID - 10.1016/j.antiviral.2024.105836 [doi]
PST - ppublish
SO  - Antiviral Res. 2024 Mar;223:105836. doi: 10.1016/j.antiviral.2024.105836. Epub 
      2024 Feb 14.